About Rho guanine nucleotide exchange factor 26
Rho guanine nucleotide exchange factor 26 (ARHGEF26) is a protein
from Homo sapiens identified by UniProt accession
Q96DR7, 871 residues long.
MolForge cross-references it against 0 known binders and
98 disease associations.
Target properties
| Protein name | Rho guanine nucleotide exchange factor 26 |
| UniProt accession | Q96DR7 |
| Gene | ARHGEF26 |
| Organism | Homo sapiens |
| Length | 871 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96DR7-F1 | alphafold | PREDICTED | 62.50 | — |
Amino-acid sequence (871 residues)
MDGESEVDFS SNSITPLWRR RSIPQPHQVL GRSKPRPQSY QSPNGLLITD FPVEDGGTLL AAQIPAQVPT ASDSRTVHRS PLLLGAQRRA VANGGTASPE YRAASPRLRR PKSPKLPKAV PGGSPKSPAN GAVTLPAPPP PPVLRPPRTP NAPAPCTPEE DLTGLTASPV PSPTANGLAA NNDSPGSGSQ SGRKAKDPER GLFPGPQKSS SEQKLPLQRL PSQENELLEN PSVVLSTNSP AALKVGKQQI IPKSLASEIK ISKSNNQNVE PHKRLLKVRS MVEGLGGPLG HAGEESEVDN DVDSPGSLRR GLRSTSYRRA VVSGFDFDSP TSSKKKNRMS QPVLKVVMED KEKFSSLGRI KKKMLKGQGT FDGEENAVLY QNYKEKALDI DSDEESEPKE QKSDEKIVIH HKPLRSTWSQ LSAVKRKGLS QTVSQEERKR QEAIFEVISS EHSYLLSLEI LIRMFKNSKE LSDTMTKTER HHLFSNITDV CEASKKFFIE LEARHQNNIF IDDISDIVEK HTASTFDPYV KYCTNEVYQQ RTLQKLLATN PSFKEVLSRI ESHEDCRNLP MISFLILPMQ RVTRLPLLMD TICQKTPKDS PKYEVCKRAL KEVSKLVRLC NEGARKMERT EMMYTINSQL EFKIKPFPLV SSSRWLVKRG ELTAYVEDTV LFSRRTSKQQ VYFFLFNDVL IITKKKSEES YNVNDYSLRD QLLVESCDNE ELNSSPGKNS STMLYSRQSS ASHLFTLTVL SNHANEKVEM LLGAETQSER ARWITALGHS SGKPPADRTS LTQVEIVRSF TAKQPDELSL QVADVVLIYQ RVSDGWYEGE RLRDGERGWF PMECAKEITC QATIDKNVER MGRLLGLETN V
Explore Rho guanine nucleotide exchange factor 26 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets